LPGO.ST
Lipigon Pharmaceuticals AB (publ) [LPGO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LPGO.ST Stock Summary
Top 10 Correlated ETFs
LPGO.ST
Top 10 Correlated Stocks
LPGO.ST
In the News
LPGO.ST Financial details
Company Rating
-
Market Cap
38.56M
Income
-12.13M
Revenue
16.41M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
22 Feb 2024
P/E
-2.66
Forward P/E
-
PEG
0.32
P/S
3.28
P/B
1.61
P/C
-
P/FCF
-3.62
Quick Ratio
6.09
Current Ratio
6.47
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.38
EPS next Y
-
EPS next Q
-
EPS this Y
-91.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-13.83%
Revenue last 5Y
56.58%
Revenue Q/Q
-
EPS Q/Q
45.07%
-
-
-
-
SMA20
-45.45%
SMA50
-20%
SMA100
-29.41%
Inst Own
-
Inst Trans
-
ROA
-51%
ROE
-82%
ROC
-0.61%
Gross Margin
100%
Oper. Margin
-82%
Profit Margin
-82%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.285-0.82
52W High
-
52W Low
-
RSI
48.26
Rel Volume
0.62
Avg Volume
569.76K
Volume
350.72K
Perf Week
9.58%
Perf Month
-46.11%
Perf Quarter
-22.28%
Perf Half Y
-28.3%
-
-
-
-
Beta
0.377
-
-
Volatility
0.01%, 0.07%
Prev Close
9.58%
Price
0.1315
Change
14.35%
Company Profile
- Volume Average 569.76K
- Market Capitalization 38.56M
- Employee 7
- CEO Dr. Stefan K. Nilsson
- Headquarters Umeå,SE
- IPO Date 2021-03-01
-
Website
https://www.lipigon.se 
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.
